Article
Carl Zeiss Optical Inc. introduced the Gradal Brevity lens.
Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in patients with X-linked retinitis pigmentosa
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
New study highlights retinopathy risk from hair dye use
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Study finds increased air pollution leads to surge in daily eye clinic visits
Study suggests visual system affected in patients with mild traumatic brain injury